Type 2 Diabetes Clinical Trials 2026: Oral GLP-1s, Retatrutide & Weekly Insulin

The GLP-1 revolution has been one of the most consequential drug class developments in a generation. What started as a glucose-lowering mechanism turned out to reduce major cardiovascular events — the LEADER trial showed a 13% relative risk reduction in MACE with liraglutide, 3P-MACE HR 0.87, p=0.01 — provide clinically meaningful weight loss, protect against kidney disease progression, and now appears to have effects on neuroinflammation and addictive behavior that nobody anticipated when the mechanism was first characterized. The 2026 trial pipeline isn't just extending that wave. It's trying to eliminate the main barrier to broader adoption (the injection), push efficacy further with triple agonism, and answer the organ-protection questions that 10 years of GLP-1 use in clinical practice has generated. Several pivotal Phase 3 readouts arriving through 2026 will substantially change how endocrinologists manage metabolic disease for the next decade.

Oral GLP-1 Agonists: Solving the Problem Nobody Admits Is a Problem

There's always been a quiet acknowledgment that the injection is a barrier. Injectable semaglutide has demonstrated 14.9% weight loss in STEP-1 and 2.46% HbA1c reduction in SURPASS-2 versus 1.86% for liraglutide. The efficacy is exceptional. But adherence data in real-world populations for injectable GLP-1 therapy sits around 55–60% at one year. Oral medications consistently outperform injectables on this metric, often by 15–20 percentage points. If you can approximate the same per-dose efficacy in an oral formulation, the population-level benefit could be substantially larger even if individual pharmacological performance is marginally lower.

Rybelsus — oral semaglutide 14 mg — was the first oral GLP-1 approved, but its strict fasting requirement (30 minutes before food or water, taken in an upright position) with bioavailability around 1% created real adherence challenges of its own. The next generation uses non-peptide small molecules that resist GI degradation entirely.

Orforglipron (Eli Lilly) is the front-runner. The ACHIEVE Phase 3 program — 6 trials, over 4,000 patients — showed HbA1c reductions of 1.3–1.6% from baseline and body weight loss of 7.9–8.6 kg over 40 weeks, comparable to injectable semaglutide and without dietary restrictions. Lilly filed for FDA approval in early 2026. Danuglipron (Pfizer) showed similar glycemic efficacy in Phase 2b but faced tolerability questions with twice-daily dosing; they're advancing a once-daily reformulation with improved GI tolerability data.

The adherence hypothesis is the real story here. If orforglipron achieves 70–75% real-world adherence where injectable semaglutide achieves 55–60%, the cardiovascular and glycemic impact at population scale could be substantial — even accounting for any modest per-patient efficacy difference. That's the bet the field is making.

Retatrutide: The Triple Agonist Data and What It Actually Means

Tirzepatide (Mounjaro/Zepbound) proved that simultaneous GLP-1 and GIP receptor activation outperformed GLP-1 alone — SURPASS-2 showed tirzepatide 15 mg achieved 2.46% HbA1c reduction versus 1.86% for semaglutide 1 mg, and SURMOUNT-1 produced 22.5% mean body weight loss in people with obesity. The mechanism of superiority over pure GLP-1 is still debated, but the clinical effect is reproducible across trials.

Retatrutide adds a third receptor: glucagon. Glucagon receptor activation increases hepatic glucose output and energy expenditure beyond what incretin hormones achieve alone. In the Phase 2 trial (NCT04881760, published NEJM 2023), dose-dependent weight loss reached 17.5% at the 4 mg dose and 24.2% at the 12 mg dose over 48 weeks — in people with obesity but without T2D. The T2D Phase 2 data showed approximately 2.2% HbA1c reduction at the highest dose with comparable or superior glycemic control versus tirzepatide head-to-head comparator arms.

The Phase 3 program is actively enrolling. Screen-failure rates in Phase 2 were modest, suggesting Phase 3 will have accessible eligibility for well-characterized T2D patients. The unresolved question isn't efficacy — that's genuinely impressive — it's tolerability at the doses required for maximum effect, and the cardiovascular outcomes data that will eventually be required before retatrutide could achieve broad clinical adoption. Those answers will take years to accumulate.

Once-Weekly Insulin: Addressing the Adherence Problem at the Basal Insulin End

Daily basal insulin injections are among the most common adherence failures in type 2 diabetes management. Real-world adherence to glargine and degludec at 6–12 months in unselected T2D populations runs considerably below clinical trial rates. Two once-weekly formulations are now completing regulatory review through distinct mechanisms:

• Insulin icodec (Novo Nordisk): The ONWARDS Phase 3 program across 6 trials demonstrated non-inferior HbA1c reduction versus daily degludec — the primary endpoint difference was +0.03% favoring degludec, within the prespecified 0.3% non-inferiority margin — with comparable rates of Level 2 clinically significant hypoglycemia. Approved in the EU and Canada. FDA decision pending as of 2026.
• Efsitora alpha / basal insulin Fc (Eli Lilly, QWINT program): Phase 3 comparing efsitora to daily degludec demonstrated non-inferiority on HbA1c in both insulin-naive and insulin-experienced T2D patients. The mechanism — fusion with an antibody Fc fragment to extend half-life — is distinct from icodec's fatty acid-albumin binding approach. Lilly submitted an NDA to the FDA in late 2025.

Both agents are actively enrolling post-approval studies and extension phases. For patients managing daily basal insulin with suboptimal adherence, these trials represent a quality-of-life improvement with no meaningful glycemic trade-off based on current data. That's a straightforward clinical case for participation.

Organ-Protective Trials: Where the Next Decade of Diabetes Medicine Gets Written

Beyond glucose control, the field has fundamentally shifted attention to what diabetes does to the organs that accumulate damage over decades — and whether GLP-1 class drugs and their successors can protect them. The FIDELITY-DKD pooled analysis of finerenone — a non-steroidal mineralocorticoid receptor antagonist — reduced the composite kidney failure risk by 20% relative risk and cardiovascular death/MI/stroke by 14% in T2D patients with CKD, on top of standard RAAS blockade. Phase 3 combination trials testing finerenone alongside GLP-1 agonists are now enrolling, testing whether these mechanisms have additive organ protection.

MASH (metabolic-associated steatohepatitis) has become the third major target. Resmetirom (Rezdiffra) received FDA approval in March 2024 for MASH with liver fibrosis — the first approved drug for this indication — after MAESTRO-NASH showed 26% MASH resolution with fibrosis improvement at 400 mg versus 10% on placebo. Multiple combination trials testing resmetirom with GLP-1 agents, and standalone semaglutide MASH studies, are recruiting T2D patients with concurrent hepatic disease. This is a large and historically underserved population.

Who Qualifies — and the One Thing to Know Before Screening

Most T2D drug trials share a common eligibility core: established type 2 diabetes (not type 1, not MODY), HbA1c in the 7.0–11.0% range (the exact window varies — some want inadequately controlled patients at 8.0%+, others want the broader T2D population at 7.0%+), stable background therapy for at least 3 months, and adequate kidney function (eGFR ≥ 30 or ≥ 45 depending on the specific drug). Most oral GLP-1 trials exclude patients already on injectable GLP-1 therapy to avoid confounding the efficacy signal.

The most common screen failure in diabetes trials is an HbA1c that falls outside the study window. Know your most recent result before you call a trial site — it's the first question they'll ask. If your HbA1c improved substantially since your last measurement, read the specific protocol language on "stable HbA1c" carefully. Some trials want inadequately controlled patients and specifically exclude recently improved values; others are indifferent to recent trajectory. That distinction matters for which trial is actually worth your time to pursue.

Key Takeaways

• Orforglipron is filing for FDA approval in 2026 with Phase 3 data showing ~1.5% HbA1c reduction and ~8 kg weight loss — no injection, no fasting requirements.
• Retatrutide's GLP-1/GIP/glucagon triple agonism produced 24.2% weight loss in Phase 2 at maximal doses; the T2D Phase 3 program is actively enrolling.
• Know your last HbA1c before contacting any diabetes trial — values outside the protocol window are the leading screen-failure cause in this space.
• Once-weekly insulin formulations (icodec, efsitora) are in FDA regulatory review with confirmed Phase 3 non-inferiority data.
• Organ-protection trials targeting kidney, liver, and cardiovascular endpoints represent the next frontier — relevant for T2D patients with CKD, MASH, or elevated CV risk beyond what current standard of care achieves.

Actionable Steps

1. Search ClinicalMetric for "diabetes" + "Recruiting" and filter to Phase 2 or Phase 3 for interventions with better-characterized safety profiles.
2. Check your last HbA1c result before contacting any trial — values outside a trial's specific window are the most common screen failure cause in diabetes studies.
3. Ask your endocrinologist if any diabetes trials at your academic medical center match your current treatment status.
4. Search for CGM and monitoring observational studies if you want to contribute without medication changes — these typically have broad eligibility and flexible visit schedules.
5. Use ClinicalMetric's condition filter with "Type 1 diabetes" or "Type 2 diabetes" separately — eligibility criteria differ significantly between the two populations.

Frequently Asked Questions